Software for clinical mutation analysis in cancer precision medicine

Important results from the project

The project had three primary goals, 1) to build a solid foundation for future development (identification of the must-have product functionalities, establishment of QMS), 2) to verify the first prototype together with a clinical partner and 3) to capitalize Oncodia for future growth.

Expected long term effects

We identified needs of the clinical and industrial users and payers trough interaction with European and American KOLs, which were later confirmed by the requirements of our clinical partner. As a result of the project we have a clear vision of what needs to be developed, an interested early adopter, and a company infrastructure to turn our prototype into a product.

Approach and implementation

As KOL and identified user needs drove further development, the QMS has been implemented but the CE/IVD marking postponed to Q4 2019. The successful completion of all packages materialized as an attractive business case and has produced a roadmap for reaching the market. The fruitful collaboration with Uppsala Akademiska Sjukhuset will continue with the aim to secure a first clinical user.